|
HS Code |
143452 |
| Iupac Name | 2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]methyl acetate |
| Molecular Formula | C19H17BrN4O2S |
| Molecular Weight | 445.34 g/mol |
| Cas Number | 1807982-77-1 |
| Appearance | Off-white to light yellow solid |
| Solubility | Soluble in DMSO, methanol |
| Storage Condition | Store at -20°C, protected from light and moisture |
| Purity | >98% (HPLC) |
| Smiles | CC(=O)OCCSc1nnc(-c2ccc3ccccc3c2C2CC2)n1Br |
As an accredited 2-[[5-Bromo-4-(4-Cyclopropylnaphthyl-1-Yl)-4H-1,2,4-Triazol-3-Yl]Thio]Methyl Acetate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 2-[[5-Bromo-4-(4-Cyclopropylnaphthyl-1-Yl)-4H-1,2,4-Triazol-3-Yl]Thio]Methyl Acetate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Walking down the aisles of chemical innovation, certain compounds call out to researchers and developers who keep one eye on technical progress and the other on marketplace needs. 2-[[5-Bromo-4-(4-Cyclopropylnaphthyl-1-Yl)-4H-1,2,4-Triazol-3-Yl]Thio]Methyl Acetate stands out as one of those specialized molecules. Its molecular structure, with a triazole ring coupled to both a bromo-naphthyl and a thioacetate group, demands attention from synthetic chemists. Instead of being another addition to stockroom shelves, this compound opens up fresh conversations about targeted design in medicinal chemistry and related advanced research.
Most conversations about this product begin with the name itself. For someone new to the field or for industry professionals critiquing trending products, the long chemical nomenclature may feel intimidating. But looking at its parts reveals why it’s making an impact:
From my own years in chemical development, each structural element signals forethought. There’s no fluff in this scaffold. Someone sat down and mapped out pathways, planned for specific outcomes, and looked several steps past the initial synthesis.
Use cases for a compound like this ripple into a few main channels: life science research, drug candidate optimization, and, less obviously, materials chemistry. For teams working on kinase inhibitors, or crafting molecules for structure-activity relationship studies, the tightly bound cyclopropylnaphthyl group sparks interest. It often translates to higher metabolic stability and sometimes better oral bioavailability, based on literature for related structures.
From an application perspective, bench scientists often use this product for scaffold hopping—a process of swapping core molecular frameworks to enhance or redirect biological activity. The modular nature of this product’s design fits into synthesis schemes where you’re iterating fast, tweaking components to see shifts in activity, solubility, or toxicity. I’ve sat in on research meetings where fragments like these formed the starting point for new development programs—either moving promising leads into preclinical evaluation or ruling out unproductive chemical spaces.
Synthetic chemists may use it to probe new catalytic cycles. The heterocyclic core, combined with thioether and ester functionalities, can coordinate with transition metals or facilitate substitution reactions that deliver analogues with distinctive three-dimensional shapes. Academic groups often seek precisely these scaffolds for publications, patent filings, or competitive grants.
Stacking this compound up against more traditional triazole derivatives quickly reveals its edge. Many available products give you a triazole embedded in a simpler aromatic system, or attached to a linear aliphatic tail. Additions like the 4-cyclopropylnaphthyl group bump up both the size and the target selectivity. From my own experience reviewing custom synthesis requests, there’s growing demand for naphthyl and cyclopropyl substituents due to their rigid structures and proven value in receptor-binding domains.
Where some triazole analogues see metabolic breakdown or phase out during later-stage studies, this one tends to persist. Researchers focusing on liver microsome stability, or early ADME (absorption, distribution, metabolism, excretion) panels, often prefer more complex, rigidified molecules. The bromine atom at the 5-position also offers a springboard for further derivatization through palladium-catalyzed coupling reactions—Suzuki, Stille, or Buchwald-Hartwig—giving synthetic chemists flexibility without building new molecules from scratch.
Unlike standard benzylated or methylated triazole esters, this acetate handles purification and post-synthetic manipulation with fewer headaches. In labs running parallel syntheses, compounds that resist hydrolysis or oxidation, like this one, save both time and resources.
Modern product offerings increasingly focus on reproducibility and reliability—not just raw purity. Quality control analysts don’t just scan a one-liner in a catalog; they read batch reports, look at chromatographic profiles, and ask about residual solvents or trace impurities. Delivering on tight analytical standards smooths project timelines, and avoids downstream complications.
Most preparations of this type list high purity, low moisture content, and minimal heavy metal residues. These statistics come up most in conversations with regulatory-facing teams, especially when moving a hit compound into a clinical candidate selection process. The nitty-gritty of lot-to-lot consistency, scalability, and documentation matters far more than splashy marketing sheets.
I have watched colleagues negotiate project hurdles: Sometimes, an available product would pass the spectral test, only to later reveal trace contaminants under LC-MS. Labs pursuing patent work or regulatory submissions need extra confidence, not just that the synthetic path is robust, but that the finished product meets the most granular quality checks.
This molecule speaks directly to the gap between commoditized, generic building blocks and highly specialized, case-by-case custom synthesis. Where academic labs want access to trending scaffolds for publication and innovation, industry researchers search for speed, reliability, and versatility in the starting materials they pick. Broadening the reach of structurally rich, multi-functional compounds feeds both creatures: the pressure to publish and the mandate to deliver scalable, practical solutions for tangible problems.
From a stewardship lens, choosing higher-performance scaffolds increases the odds of identifying promising bioactive molecules with fewer false positives. Investment in diverse, high-value building blocks can accelerate timelines. Teams can target new biological pathways or binding pockets, which is especially important as targets in oncology, anti-infectives, or neurodegenerative diseases become ever more complex.
The trend toward modular synthesis, which this product embodies, makes chemistry more agile. It means fewer roadblocks and smarter use of funding—two things chemists feel every time they tackle a new synthetic challenge.
Bringing a compound like this to bench and scale presents challenges. Synthetic bottlenecks pop up, especially as ring systems or substituents become more involved. Commercial suppliers need to keep pace with actual research requirements, updating processes to reduce byproducts or address regulatory pushes for green chemistry. I’ve seen inefficiencies in supply chains stall projects when researchers can’t get reliable access to high-purity material.
Quality and documentation, in practice, matter just as much as molecular innovation. Projects live and die by well-documented data packages—analytical spectra, stability reports, impurity profiles. Labs making clinical or industrial investments need supplier transparency. Forward-thinking vendors offer complete batch records, full traceability, and extra data (from crystalline forms to polymorph studies) so end users can navigate later development stages with fewer surprises.
On the technical side, adopting more environmentally benign synthetic steps could improve commercial adoption. For example, swapping out harsh halogenation protocols or optimizing triazole-forming reactions creates less hazardous waste. Operations built around flow chemistry or biocatalysis, rather than strictly thermal batch synthesis, bring down costs and environmental impact.
Training and education also shape how emerging researchers approach these advanced molecules. For many early-career chemists, deciphering the advantages or limitations of novel frameworks comes with hands-on work. Workshops, accessible data, and real-world case studies move the conversation past simple catalog descriptions.
As markets and technology move together, demand for precision-designed intermediates like 2-[[5-Bromo-4-(4-Cyclopropylnaphthyl-1-Yl)-4H-1,2,4-Triazol-3-Yl]Thio]Methyl Acetate will push suppliers and researchers to align on transparency, quality, and adaptability. From my perspective, those who bridge the gap between high-end synthesis and real-world practicality stand to shape not just next year’s pipeline, but the entire ecosystem of drug and material discovery.
Small changes in molecular scaffolds lead to outsized impacts in both laboratory and commercial outcomes. This compound isn't just a research tool—it’s a reflection of the larger movement toward smarter, more adaptable chemistry for modern challenges. Better scaffolds empower faster synthesis, deeper understanding, and faster response to global needs.
Leaning into collaboration between established suppliers and research institutions can strengthen the supply and demand loop. Joint projects that share insights across process development, green chemistry adoption, and end-user needs help align priorities. Pooled efforts lighten the risk for any individual group, and reveal shortcuts or efficiency boosts that might get missed on a slower timeline.
Wider data sharing around this class of compounds, from biological testing to synthetic tweaks, accelerates the feedback cycle in medicinal chemistry. The proof often lies in real-world case studies and comparative assays. Researchers are likelier to adopt a new scaffold if they know how others have succeeded—or tripped—on similar ground.
From an educational standpoint, deeper dives into the “why” behind these frameworks belong in advanced curricula and workshops. By teaching the interplay between scaffold design, metabolic stability, and functional group compatibility, programs prepare chemists to make sharper, more strategic choices, upstream instead of waiting for project setbacks downstream.
Moving beyond commodity chemicals, the industry’s growth depends on choosing frameworks like this triazole-based acetate. It's not just the structure—it’s the readiness for fast adaptation, the flexibility across diverse chemistries, and the clear attention to performance that set it apart. I see real traction every time project teams commit to exploiting everything these molecules can offer. They drive not only research outcomes but also accelerate progress across therapeutic and industrial challenges.
By focusing on substance—not just style—chemists working with advanced compounds continually redefine what’s possible. Carefully chosen, thoughtfully developed molecules create a ripple effect, benefiting project timelines, research productivity, clinical prospects, and the larger community. As opportunities expand and barriers break down, innovations like 2-[[5-Bromo-4-(4-Cyclopropylnaphthyl-1-Yl)-4H-1,2,4-Triazol-3-Yl]Thio]Methyl Acetate aren’t just inputs—they’re strategic levers in the quest for scientific progress and better outcomes for all.